Programs
The company’s approach to developing novel therapeutics draws on decades of psychedelic research into a variety of mental health conditions.
reunionneuro.comCrawled Oct 15, 2026
The company’s approach to developing novel therapeutics draws on decades of psychedelic research into a variety of mental health conditions.
Reunion is developing investigational therapeutics intended to improve patient outcomes and support a rapid return to daily activities.
Reunion Neuroscience | 30 Duncan Street, Lower North Level | Toronto, Ontario M5V2C3
Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience is developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience appoints **Sahil V. Kirpekar, M.D.** as its new **President and CEO**. Kirpekar brings over two decades of experience in biopharma, specializing in psychiatric therapeutic development and organizational leadership. His expertise includes pipeline management and scaling companies in the life sciences sector.
Reunion Neuroscience names **Sahil V. Kirpekar, M.D.** as its new **President and CEO**, bringing deep expertise in biopharma leadership. His background includes building organizations and advancing psychiatric therapeutic pipelines. The appointment underscores the company’s focus on scaling its neuroscience research and development efforts.
Reunion Neuroscience presents full results from its **RECONNECT Phase 2 trial** evaluating **luvesilocin** for **moderate-to-severe postpartum depression (PPD)** in adult female patients. The data will be shared in an oral presentation at the **American Society of Clinical Psychopharmacology (ASCP) and American Psychiatric Association (APA) annual meetings**. The company focuses on psychedelic-inspired therapies for underserved mental health disorders.
The U.S. FDA grants **Reunion Neuroscience’s** psychedelic compound **Luvesilocin (RE104)** Breakthrough Therapy designation. The decision follows positive results from the **RECONNECT Phase 2 clinical trial**, supporting its potential as a novel treatment. The designation accelerates development and review for serious conditions where unmet medical needs exist.
Reunion Neuroscience reports that its **RE104** drug candidate meets the primary endpoint in a Phase 2 trial for postpartum depression (PPD). The 30mg dose achieves a **23.0-point reduction** in the Montgomery-Åsberg Depression Rating Scale (MADRS) by Day 7, with statistical significance (p=0.0094). Data is presented at the **ACNP Annual Meeting**.
Reunion Neuroscience aligns with the FDA on a registrational path for its drug **RE104** in treating **postpartum depression (PPD)** and plans to begin a **Phase 3 trial in 2026**. The company is also enrolling a **Phase 2 trial (REKINDLE)** for RE104 in **adjustment disorder (AjD)**, with initial data expected in **early 2027**. Additionally, Reunion aims to initiate a **Phase 2 trial (RECLAIM)** for **generalized anxiety disorder (GAD)** in the first quarter of 2026.
Reunion Neuroscience begins dosing the first patient in its **REKINDLE Phase 2 trial** of **RE104**, a potential treatment for **Adjustment Disorder (AjD)** in patients with cancer and other serious illnesses. The company targets an unmet medical need, as no FDA-approved therapies currently exist for this condition. RE104 is being evaluated for safety and efficacy in this patient population.

Reunion Neuroscience develops investigational serotonergic medicines for mental health conditions.